Experimental drug offered to stem cell transplant patients with rare blood disorder
NCT ID NCT04247906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem cell transplant and meet specific criteria to participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- narsoplimab
- What this could lead to
- If successful, this could offer a treatment option for patients with a serious complication after stem cell transplant.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are uncertain. The drug may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.